• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,267.34 -508.40
( -0.68%)
Global Indices
Nasdaq
51,069.65 379.68
(0.75%)
Dow Jones
7,605.10 20.47
(0.27%)
Hang Seng
67,130.34 800.84
(1.21%)
Nikkei 225
10,313.41 -95.87
(-0.92%)
Forex
USD-INR
95.93 0.16
(0.16%)
EUR-INR
111.54 0.10
(0.09%)
GBP-INR
128.71 -0.01
(-0.01%)
JPY-INR
0.60 0.00
(0.17%)

EQUITY - MARKET SCREENER

Concord Biotech Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
543960
INE338H01029
174.4719509
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CONCORDBIO
34.55
10972.67
EPS(TTM)
Face Value()
Div & Yield %
30.36
1
0.83
 

Jindal Saw consolidated net profit declines 52.13% in the March 2026 quarter
Apr 28,2026
Net profit of Jindal Saw declined 52.13% to Rs 139.43 crore in the quarter ended March 2026 as against Rs 291.28 crore during the previous quarter ended March 2025. Sales declined 8.19% to Rs 4633.48 crore in the quarter ended March 2026 as against Rs 5046.59 crore during the previous quarter ended March 2025.

For the full year,net profit declined 44.01% to Rs 973.35 crore in the year ended March 2026 as against Rs 1738.37 crore during the previous year ended March 2025. Sales declined 14.08% to Rs 17895.17 crore in the year ended March 2026 as against Rs 20828.89 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales4633.485046.59 -8 17895.1720828.89 -14
OPM %10.3114.59 -12.3816.46 -
PBDT338.39625.13 -46 1706.202951.02 -42
PBT171.65472.51 -64 1075.712348.96 -54
NP139.43291.28 -52 973.351738.37 -44